Ambrosini V - Search Results

1

Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis.

Ricci C, Casadei R, Taffurelli G, Campana D, Ambrosini V, Pacilio CA, Santini D, Brighi N, Minni F. Ricci C, et al. Among authors: ambrosini v. Pancreatology. 2018 Apr;18(3):313-317. doi: 10.1016/j.pan.2018.02.008. Epub 2018 Feb 21. Pancreatology. 2018. PMID: 29487026

2

Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.

Ambrosini V, Tomassetti P, Rubello D, Campana D, Nanni C, Castellucci P, Farsad M, Montini G, Al-Nahhas A, Franchi R, Fanti S. Ambrosini V, et al. Nucl Med Commun. 2007 Jun;28(6):473-7. doi: 10.1097/MNM.0b013e328182d606. Nucl Med Commun. 2007. PMID: 17460538 Clinical Trial.

3

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S. Ambrosini V, et al. Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17. Eur J Nucl Med Mol Imaging. 2008. PMID: 18418596

4

(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S. Ambrosini V, et al. Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):722-7. doi: 10.1007/s00259-009-1349-9. Epub 2010 Jan 27. Eur J Nucl Med Mol Imaging. 2010. PMID: 20107793

5

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors.

Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, Ceccarelli C, Nori F, Franchi R, Corinaldesi R, Tomassetti P. Campana D, et al. Among authors: ambrosini v. J Nucl Med. 2010 Mar;51(3):353-9. doi: 10.2967/jnumed.109.066662. Epub 2010 Feb 11. J Nucl Med. 2010. PMID: 20150249 Free article. Clinical Trial.

6

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.

Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, Montini GC, Tomassetti P, Paganelli G, Fanti S. Ambrosini V, et al. J Nucl Med. 2010 May;51(5):669-73. doi: 10.2967/jnumed.109.071712. Epub 2010 Apr 15. J Nucl Med. 2010. PMID: 20395323 Free article.

7

PET/CT with 68Gallium-DOTA-peptides in NET: an overview.

Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S. Ambrosini V, et al. Eur J Radiol. 2011 Nov;80(2):e116-9. doi: 10.1016/j.ejrad.2010.07.022. Epub 2010 Aug 25. Eur J Radiol. 2011. PMID: 20800401 Review.

8

68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.

Ambrosini V, Campana D, Allegri V, Opocher G, Fanti S. Ambrosini V, et al. Clin Nucl Med. 2011 Jan;36(1):64-5. doi: 10.1097/RLU.0b013e3181fef14a. Clin Nucl Med. 2011. PMID: 21157217

9

⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

Ambrosini V, Campana D, Tomassetti P, Fanti S. Ambrosini V, et al. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S52-60. doi: 10.1007/s00259-011-1989-4. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388622 Review.

10

Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?

Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D, Fanti S. Ambrosini V, et al. Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1278-83. doi: 10.1007/s00259-012-2146-4. Epub 2012 May 15. Eur J Nucl Med Mol Imaging. 2012. PMID: 22584487

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters